Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker

L. Noehr-Jensen (1) , S. T. Zwisler (1, 2) , F. Larsen (3) , S. H. Sindrup (2) , P. Damkier (1, 4) , F. Nielsen (1) , K. Brosen (1)

1 Institute of Public Health, Clinical Pharmacology
2 Department of Clinical Neurology
3 Clinical Pharmacology & Pharmacokinetics
4 Department of Biochemistry, Pharmacology and Genetics

Mots clés: Biomarker; CYP2C19; Escitalopram; Pharmacodynamics; Pharmacokinetics; Pupillometry

L. Noehr-Jensen, S. T. Zwisler, F. Larsen, S. H. Sindrup, P. Damkier, et al.. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. European Journal of Clinical Pharmacology, 2009, 65 (9), pp.887-894. ⟨10.1007/s00228-009-0657-0⟩. ⟨hal-00534960⟩